CtBP1 is expressed in melanoma and represses the transcription of p16INK4a and Brca1

Journal of Investigative Dermatology

Volumn 133, Issue 5, 2013, Pages 1294-1301

  Deng, Hui ^a,b   Liu, Jing ^a   Deng, Yu ^a   Han, Gangwen ^a   Shellman, Yiqun G ^a   Robinson, Steven E ^a   Tentler, John J ^a   Robinson, William A ^a   Norris, David A ^a   Wang, Xiao Jing ^a   Zhang, Qinghong ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CARBOXYL TERMINAL BINDING PROTEIN 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; DNA DAMAGE; DNA REPAIR; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA; MELANOMA CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84876668523     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.487     Document Type: Article

References (44)

1. Arozarena I, Bischof H, Gilby D et al. (2011) In melanoma, beta-catenin is a suppressor of invasion. Oncogene 30:4531-43
2. BCLC (1999) Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 91:1310-6
3. Bergman LM, Birts CN, Darley M et al. (2009) CtBPs promote cell survival through the maintenance of mitotic fidelity. Mol Cell Biol 29:4539-51
4. Bornstein S, White R, Malkoski S et al. (2009) Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation. J Clin Invest 119:3408-19
5. Box NF, Duffy DL, Chen W et al. (2001) MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 69:765-73
6. Cannon-Albright LA, Goldgar DE, Neuhausen S et al. (1994a) Localization of the 9p melanoma susceptibility locus (MLM) to a 2-cM region between D9S736 and D9S171. Genomics 23:265-8
7. Cannon-Albright LA, Meyer LJ, Goldgar DE et al. (1994b) Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM). Cancer Res 54:6041-4
8. Chinnadurai G (2002) CtBP, an unconventional transcriptional corepressor in development and oncogenesis. Mol Cell 9:213-24
9. Chinnadurai G (2009) The transcriptional corepressor CtBP: a foe of multiple tumor suppressors. Cancer Res 69:731-4
10. D'Andrea AD, Grompe M (2003) The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 3:23-34
11. Deng Y, Deng H, Liu J et al. (2012) Transcriptional down-regulation of Brca1 and E-cadherin by CtBP1 in breast cancer. Mol Carcinog 51:500-7
12. Deng Y, Liu J, Han G et al. (2010) Redox-dependent Brca1 transcriptional regulation by an NADH-sensor CtBP1. Oncogene 29:6603-8
13. Di LJ, Fernandez AG, De Siervi A et al. (2010) Transcriptional regulation of BRCA1 expression by a metabolic switch. Nat Struct Mol Biol 17:1406-13
14. Gaur A, Jewell DA, Liang Y et al. (2007) Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 67:2456-68
15. Grooteclaes M, Deveraux Q, Hildebrand J et al. (2003) C-terminal-binding protein corepresses epithelial and proapoptotic gene expression programs. Proc Natl Acad Sci USA 100:4568-73
16. Hall HI, Miller DR, Rogers JD et al. (1999) Update on the incidence and mortality from melanoma in the United States. J Am Acad Dermatol 40:35-42
17. Hearle N, Damato BE, Humphreys J et al. (2003) Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma. Invest Ophthalmol Vis Sci 44:458-62
18. Hobel S, Aigner A (2010) Polyethylenimine (PEI)/siRNA-mediated gene knockdown in vitro and in vivo. Methods Mol Biol 623:283-97
19. Hoot KE, Lighthall J, Han G et al. (2008) Keratinocyte-specific Smad2 ablation results in increased epithelial-mesenchymal transition during skin cancer formation and progression. J Clin Invest 118:2722-32
20. Hussussian CJ, Struewing JP, Goldstein AM et al. (1994) Germline p16 mutations in familial melanoma. Nat Genet 8:15-21
21. Jenkins NC, Liu T, Cassidy P et al. (2011) The p16(INK4A) tumor suppressor regulates cellular oxidative stress. Oncogene 30:265-74
22. Jonsson A, Tuominen R, Grafstrom E et al. (2010) High frequency of p16(INK4A) promoter methylation in NRAS-mutated cutaneous melanoma. J Invest Dermatol 130:2809-17
23. Kadouri L, Temper M, Grenader T et al. (2009) Absence of founder BRCA1 and BRCA2 mutations in cutaneous malignant melanoma patients of Ashke-nazi origin. Fam Cancer 8:29-32
24. Krimpenfort P, Quon KC, Mooi WJ et al. (2001) Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 413:83-6
25. Kumar R, Smeds J, Lundh Rozell B et al. (1999) Loss of heterozygosity at chromosome 9p21 (INK4-p14ARF locus): homozygous deletions and mutations in the p16 and p14ARF genes in sporadic primary melanomas. Melanoma Res 9:138-47
26. Larson AA, Leachman SA, Eliason MJ et al. (2007) Population-based assessment of non-melanoma cancer risk in relatives of cutaneous melanoma probands. J Invest Dermatol 127:183-8
27. Lu J, Getz G, Miska EA et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435:834-8
28. MacKie RM, Hauschild A, Eggermont AM (2009) Epidemiology of invasive cutaneous melanoma. Ann Oncol 20(Suppl 6):vi1-7
29. Monahan KB, Rozenberg GI, Krishnamurthy J et al. (2010) Somatic p16(INK4a) loss accelerates melanomagenesis. Oncogene 29:5809-17
30. Mroz EA, Baird AH, Michaud WA et al. (2008) COOH-terminal binding protein regulates expression of the p16INK4A tumor suppressor and senescence in primary human cells. Cancer Res 68:6049-53
31. Mueller CR, Roskelley CD (2003) Regulation of BRCA1 expression and its relationship to sporadic breast cancer. Breast Cancer Res 5:45-52
32. Palavalli LH, Prickett TD, Wunderlich JR et al. (2009) Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet 41:518-20
33. Paliwal S, Pande S, Kovi RC et al. (2006) Targeting of C-terminal binding protein (CtBP) by ARF results in p53-independent apoptosis. Mol Cell Biol 26:2360-72
34. Pho L, Grossman D, Leachman SA (2006) Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. Curr Opin Oncol 18:173-9
35. Pillai RS, Bhattacharyya SN, Filipowicz W (2007) Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 17:118-26
36. Polsky D, Young AZ, Busam KJ et al. (2001) The transcriptional repressor of p16/Ink4a, Id1, is up-regulated in early melanomas. Cancer Res 61:6008-11
37. Poser I, Golob M, Weidner M et al. (2002) Down-regulation of COOH-terminal binding protein expression in malignant melanomas leads to induction of MIA expression. Cancer Res 62:5962-6
38. Seltzer MH, Leachman SA (2008) Breast cancer and melanoma in the same pedigree. Dermatol Online J 14:1
39. Shen SX, Weaver Z, Xu X et al. (1998) A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene 17:3115-24
40. Tyagi A, Gu M, Takahata T et al. (2011) Resveratrol selectively induces DNA Damage, independent of Smad4 expression, in its efficacy against human head and neck squamous cell carcinoma. Clin Cancer Res 17:5402-11
41. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ et al. (2005) Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 42:711-9
42. Yang J, Luan J, Yu Y et al. (2001) Induction of melanoma in murine macrophage inflammatory protein 2 transgenic mice heterozygous for inhibitor of kinase/alternate reading frame. Cancer Res 61:8150-7
43. Zhang Q, Wang SY, Nottke AC et al. (2006) Redox sensor CtBP mediates hypoxia-induced tumor cell migration. Proc Natl Acad Sci USA 103:9029-33
44. Zhang Q, Yoshimatsu Y, Hildebrand J et al. (2003) Homeodomain interacting protein kinase 2 promotes apoptosis by downregulating the transcriptional corepressor CtBP. Cell 115:177-86